<DOC>
	<DOC>NCT02072213</DOC>
	<brief_summary>Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers</brief_summary>
	<brief_title>A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers</brief_title>
	<detailed_description>GL2702 GLARS-NF1 tablet is controlled released formulation which is invented by GL Pharm Tech Corp.</detailed_description>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>20~45 years old, Healthy Adult Male Subject Body Weight ≥ 50kg and Ideal Body Weight ≤ ±20% ALT or AST &gt; 1.25 times (Upper Normal Range) Total Bilirubin &gt; 1.5 times (Upper Normal Range) CPK &gt; 2 times (Upper Normal Range) BUN or Creatinine &gt; Normal Range Systolic BP &gt; 160mmHg or &lt; 80mmHg, Diastolic BP &gt; 100mmHg or &lt; 50mmHg</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Tamsulosin,controlled release formulation</keyword>
</DOC>